

CURRICULUM VITAE
BRIAN PEI LIM LEE
JANUARY 7, 2025

PERSONAL INFORMATION:

Work

2250 Alcazar Street
Los Angeles, CA
90089
Work Email: brian.lee@med.usc.edu

EDUCATION AND PROFESSIONAL APPOINTMENTS

EDUCATION:

2010 *B.A., summa cum laude, Seven-Year Combined B.A./M.D. Program, Boston University, Boston*

2013 *M.D., summa cum laude, Boston University School of Medicine, Boston*
 Class Rank 1 of 176 students

2019 *M.A.S., Masters in Clinical Research, University of California, San Francisco, San Francisco*

POST-GRADUATE TRAINING:

2013-2016 *Residency, Internal Medicine, Sanjay Desai, Medicine, Johns Hopkins Hospital, Baltimore*

2016-2019 *Fellowship, Gastroenterology, Norah Terrault, Medicine, University of California, San Francisco*

2019-2020 *Advanced Fellowship, Transplant Hepatology, Norah Terrault, Medicine, University of California, San Francisco*

ACADEMIC APPOINTMENTS:

2020-2024 *Assistant Professor of Clinical Medicine, Department of Medicine, Keck School of Medicine of USC, Los Angeles, CA, USA*

2024- *Associate Professor of Clinical Medicine, Department of Medicine, Keck School of Medicine of USC, Los Angeles, CA, USA*

LICENSURE, CERTIFICATIONS

LICENSURE:

2019 *142953, California, Active*

BOARD CERTIFICATION OR ELIGIBILITY:

2016 *Internal Medicine, Active*

2019 *Gastroenterology, Active*

2020 *Transplant Hepatology, Active*

SPECIALTY CERTIFICATION:

2016 *Internal Medicine, Active*

2019 *Gastroenterology, Active*

2020 *Transplant Hepatology, Active*

OTHER CERTIFICATIONS OR EXAMINATIONS:

N/A

N/A

HONORS, AWARDS:

Year	Description	Awarding agency, address, city
2007	College of Arts and Science College Scholar (Top 5% of Class)	Boston University, Boston
2008	Distinguished Sophomore Award (Top 40 Students of Class Year)	Boston University, Boston
2010	Summa Cum Laude - B.A.	Boston University, Boston
2010	Phi Beta Kappa	Boston University, Boston
2013	Alpha Omega Alpha (AOA)	Boston University School of Medicine, Boston
2013	Dean Elaenor Tyler Memorial Award	Boston University School of Medicine, Boston
2013	Summa Cum Laude – M.D.	Boston University School of Medicine, Boston
2016	Johns Hopkins Resident Teaching Award	Johns Hopkins Hospital, Baltimore
2017	International Liver Transplantation Society (ILTS) Young Investigator Award	International Liver Transplantation Society (ILTS)
2017	American Association for the Study of Liver Diseases (AASLD) Young Investigator Travel Award	American Association for the Study of Liver Diseases (AASLD)
2017	European Association for the Study of the Liver (EASL) Young Investigator Award	European Association for the Study of the Liver (EASL)
2018	American Transplant Congress (ATC) Young Investigator Award	American Society of Transplantation (AST)
2018	American Association for the Study of Liver Diseases (AASLD) Clinical/Translational Early Career Investigator Award	American Association for the Study of Liver Diseases (AASLD)
2018	American Transplant Congress (ATC) Young Investigator Award	American Society of Transplantation (AST)
2019	European Association for the Study of the Liver (EASL) Young Investigator Award	European Association for the Study of the Liver (EASL)

TEACHING**DIDACTIC TEACHING:**

University of Southern California 2020-	Clinical Research Lecture Series	1h per month	Lecturer
University of Southern California 2020-	KSOM 1 st year Medical Students GI course	2h	Lecturer
University of Southern California 2020-	Keck GI Fellowship Core Lecture Series	2h	Lecturer
2020-	Keck Transplant Hepatology Core Lecture Series	2h	Lecturer

CME COURSES DEVELOPED: N/A

Institution Year-Year	Course Name	Units/Hrs	Role

UNDERGRADUATE, GRADUATE AND MEDICAL STUDENT (OR OTHER) MENTORSHIP:

Year-Year	Trainee Name	Trainee Type	Dissertation/Thesis/Project Title
2020-	Aidan Vosooghi	Medical Student	Acute-on-Chronic Liver Failure, Alcohol-Associated Liver Disease
2020-	Hirsh Elhence	Medical Student	Healthy Days at Home among Patients with Cirrhosis
2024-	Kalpana Gopalkrishnan	Medical Student	National Trends and Contributors to Advanced Alcohol-Associated Liver Disease
2024-	Emmanuelle Hodara	Medical Student	Metabolic Risk Factors and Alcohol Use Among US Emerging Adults
2024-	Sean Lee	Medical Student	Outcomes among Liver Transplant Waitlist Registrants
2024-	Yinan Su	Medical Student	Association of Vinyl Chloride with Advanced Chronic Liver Disease
2024-	Alexander Rueda	PhD Student	Ambulatory Care in Liver Disease
2024-	Qiulin Wang	PhD Student	Cardiometabolic risk factors in Liver Disease

GRADUATE STUDENT THESIS, EXAM AND DISSERTATION COMMITTEES:

Year-Year	Trainee Name	Committee Type	Student Department
2023-	Divya Ayyala	Masters Thesis	Medicine
2024-	Matthew Dukewich	Masters Thesis	Medicine

POSTGRADUATE MENTORSHIP:

Year-Year	Trainee Name	If past trainee, current position and location
2021-	Gal Sadlik	Internal Medicine Resident, USC
2022-	Matthew Dukewich	GI T32 Fellow, USC
2022-	William Minteer	GI Fellow, USC
2022-	Jin Kim	Internal Medicine Resident, USC
2023-	Gurmehr Brar	Internal Medicine Resident, USC
2023-	Rachan Narala	Internal Medicine Resident, USC
2024-	Kevin Tang	GI Fellow, USC
2024-	Philip Zhang	GI T32 Fellow, USC

MENTORSHIP OF FACULTY:

Year-Year	Mentee Name	Mentee Department
2022-	Divya Ayyala	Medicine

SERVICE

DEPARTMENT SERVICE:

Year-Year	Position, Committee	Organization/Institution
2021-	Hepatology Fellowship Interviewer	USC
2022-	Gastroenterology Fellowship Interviewer	USC

MEDICAL SCHOOL SERVICE:

Year-Year	Position, Committee	Organization/Institution
2021-	GI Curriculum Lecturer	USC Keck School of Medicine

HOSPITAL OR MEDICAL GROUP SERVICE:

Year-Year	Position, Committee	Organization/Institution
2022	Expert, Conversations with Rod	Keck Medicine of USC, Leadership Forum

UNIVERSITY SERVICE: N/A

Year-Year	Position, Committee	Organization/Institution
PROFESSIONAL SERVICE:		
2021-2023	Steering Committee Member, Annual Meeting Education Committee	American Association for the Study of Liver Diseases (AASLD)
2021-	Steering Committee Member, AASLD Alcohol-Associated Liver Disease SIG	American Association for the Study of Liver Diseases (AASLD)
2021-	Member, Planning Committee	NIAAA Clinical Trial Design Workshop
2021-2022	Expert Witness	Medi-Cal Department of Healthcare Services
2023	Voting Member	FDA Gastrointestinal Drugs Advisory Committee
2024-	Standing Voting Member	FDA Gastrointestinal Drugs Advisory Committee
2024	Voting Member	FDA Pharmacy Compounding Advisory Committee
CONSULTANTSHIPS AND ADVISORY BOARDS:		
Year	Position, Board	Organization/Hospital/School, Institution
2023-	Advisory Board Member	Novo Nordisk
2023-	Advisory Board Member	GlaxoSmithKline
2023-	Advisory Board Member	HepaTx
2023	Consultant	DURECT
2023	Consultant	Ipsen
2024	Consultant	CymaBay
2024-	Advisory Board Member	AltImmune
PROFESSIONAL SOCIETY MEMBERSHIPS:		
2014-	American Association for the Study of Liver Diseases (AASLD)	
2017-	American Society of Transplantation (AST)	
2017-	American College of Gastroenterology (ACG)	
2017-	European Association for the Study of the Liver (EASL)	
2019-	American Gastroenterology Association (AGA)	
COMMUNITY SERVICE:		
Year-Year	Position	Organization/Institution, City, Role or Activity
2021	Volunteer	Keck Medical Center of USC COVID-19 Inpatient Attending
MAJOR LEADERSHIP POSITIONS: (E.G., DEAN, CHAIR, INSTITUTE DIRECTOR, HOSPITAL ADMINISTRATION, ETC.): N/A		
Year-Year	Position	Narrative listing Accomplishments- or add appendix
<u>Summary of Service Activities</u>		
University Service—I am actively engaged in service to USC.		
<ol style="list-style-type: none"> 1) Mentor. I am an active mentor at all levels of training, including medical students, medical residents, clinical fellows, research fellows, and junior faculty. 2) I have served in screening, interviewing, and selecting fellows for our Transplant Hepatology and Gastroenterology programs. 3) Lecturer. I am a lecturer in 4 core curriculums at USC, including for 1st year medical students, gastroenterology core series, transplant hepatology core series, and a core research learning series. 4) COVID—In January 2021, I served as a volunteer inpatient attending for the COVID-19 service. 5) Novel multidisciplinary clinic—I established the multidisciplinary Alcohol-associated hepatitis Bridge Clinic (ABC) at Los Angeles General Medicine Center (LAGMC) in 2022, integrating treatment for alcohol use disorder and alcohol-associated liver disease among patients recently discharged after hospitalization for alcohol-associated hepatitis in a safety-net hospital. 6) Novel integrated alcohol transplant clinic—I am set to launch the Transplant for Alcohol Integrated Liver (TRAIL) clinic in 2025 at Keck Medical Center, a multi-disciplinary integrated clinic for pre- and post- 		

transplant care for high-risk liver transplant candidates and recipients with alcohol-associated liver disease, including hepatology, transplant surgery, addiction medicine, social work, nutritionist, and pharmacist care inclusive under one roof. This is the first integrated multi-disciplinary clinic for alcohol-associated liver disease that spans from pre- through post-transplant care in the USA. I established this clinic from conception, including business plan, job descriptions, and logistics.

7) Multi-disciplinary Quality Improvement initiatives for alcohol-associated liver disease—I engaged multiple stakeholders, including social workers, hepatologists, surgeons, addiction specialist, transplant administrators, and hospital executive leadership to create new evidence-based protocols for early transplant selection processes, an inter-hospital transfer checklist for remote early transplant evaluation, and decision pathways for addiction pharmacotherapy in our hepatology/transplant clinics.

Service to Outside Institutions—I am actively engaged in service to organizations outside USC.

- 1) American Association for the Study of Liver Diseases. I have service as a steering committee member for various committees, including Annual Meeting Education and the Alcohol-Associated Liver Disease Special Interest Group.
- 2) I am on the editorial board of *Liver Transplantation*, *Hepatology Communications* and guest editor for alcohol-associated liver disease in *Clinical Liver Disease*, which are 3 official journals of the American Associated for the Study of Liver Diseases.
- 3) NIAAA—I served on the NIAAA Task Force for guidance recommendations to design clinical trials that address alcohol use and alcohol-associated liver disease. I was chosen as leader of the Hepatology Working Group among international experts in this field, and am first-author of our guidelines document published in *Nature Reviews Gastroenterology & Hepatology*. I have particular interest in clinical trial design in the setting of concomitant alcohol use, metabolic dysfunction, and potential liver-related adverse events.

Advocacy and Public Service

- 1) National Transplant Policy—I am actively engaged in advocacy to change national transplant policy to bridge disparities in access to liver transplant. Examples include: (i) I led a national study of liver transplant access and outcomes in unauthorized immigrants, which led OPTN (national regulatory organization for transplant) to release a new guidance document to address access to unauthorized immigrants in 2021 across the United States; (ii) I led a multi-center initiative to assess the accuracy of alcohol-associated hepatitis in the national transplant registry, which led to national change in coding of alcohol-associated liver disease in 2022. (iii) My research and advocacy in early liver transplantation in alcohol-associated hepatitis led to revisions in national practice guidelines from the American College of Gastroenterologists (2018), American Association for the Study of Liver Diseases (2019), and the American Society of Transplantation (2020).
- 2) California Transplant Policy—I formed and led a group of stakeholders, including patient advocates, and directly petitioned to Medi-Cal leadership (13 million+ enrollees in California) serving as expert witness, regarding inequitable access to liver transplant access in patients with alcohol-associated liver disease with state Medicaid insurance, which led to official state-wide policy change in February 2022.
- 3) FDA—I serve as a standing voting member of the Gastrointestinal Drugs Advisory Committee for the FDA. The committee reviews and evaluates the safety and effectiveness of investigational human drug products for the treatment of gastrointestinal diseases and makes appropriate recommendations to the US Commissioner of Food and Drugs. I have also served on the FDA Pharmacy Compounding Advisory Committee, providing advice on scientific, technical, and medical issues concerning drug compounding.

RESEARCH AND SCHOLARSHIP

EDITORSHIPS AND EDITORIAL BOARDS: N/A

Year-Year	Position	Journal/Board Name
2024-	Editorial Board	Liver Transplantation
2022-	Editorial Board	Hepatology Communications
2022-2023	Guest Editor	Clinical Liver Disease

MANUSCRIPT REVIEW:

2018-	Gastroenterology
2018-	American Journal of Gastroenterology
2018-	Clinical Gastroenterology and Hepatology
2018-	Liver Transplantation
2018-	Digestive Diseases and Sciences
2019-	Hepatology Communications
2020-	General Hospital Psychiatry
2020-	Drug and Alcohol Dependence
2020-	Journal of Clinical Medicine
2021-	International Journal of Environmental Research and Public Health
2021-	Viruses
2021-	American Journal of Transplantation
2021-	Lancet Gastroenterology & Hepatology
2021-	Journal of Hepatology
2021-	Hepatology
2021-	Scientific Reports
2024-	The Lancet
2025-	New England Journal of Medicine

GRANT REVIEWS: N/A

Year Description Awarding agency, City, State, Country

MAJOR AREAS OF RESEARCH INTEREST

Research Areas

1. Metabolic risk factors and intersection with alcohol in the progression of metabolic liver disease
2. Early liver transplantation in alcohol hepatitis
3. Alcohol-associated liver disease
4. Health disparities and policy
5. Clinical trials
6. Translational Research

GRANT SUPPORT - CURRENT:

Grant No. (PI) R01AA030960 (Terrault)	Dates of Award 8/1/2023-7/31/30
Agency: NIAAA	Percent Effort 10%
<i>Title American Consortium of Early Liver Transplantation-Prospective Alcohol-associated liver disease Cohort Evaluation (ACCELERATE-PACE)</i>	
<i>Description This multi-center study will examine the patient selection process for early liver transplantation, identify strategies most helpful to prevent return to alcohol use and to optimize long-term health after transplant.</i>	
<i>Role: Co-I</i>	
<i>Total Direct Costs \$2,450,000</i>	
Grant No. (PI) K23AA029752 (Lee)	Dates of Award 7/15/2022-6/30/26
Agency: NIAAA	Percent Effort 75%
<i>Title Estimating the Contribution of Alcohol and Metabolic Risk to Liver Disease Progression to Inform Personalized Interventions</i>	
<i>Description We are assessing the longitudinal interactions of alcohol and metabolic risks on liver fibrosis, aiming to provide more individualized prognostic information; (ii) proprotein convertase subtilisin kexin type 9 (PCSK9), a novel biomarker and potential therapeutic target in ALD.</i>	
<i>Role: PI</i>	
<i>Total Direct Costs \$771,552</i>	
Grant No. (PI) Fan	Dates of Award 1/1/2021-12/31/22
Agency: NIAAA	Percent Effort 0
<i>Title Multiparametric MR mapping in short-term management of alcoholic hepatitis</i>	
<i>Description We are using multiparametric MR mapping (mpMR) among patients hospitalized with severe alcohol-associated hepatitis (AH) at discharge, 14 days, and 30 days, to assess the utility of mpMR in predicting 1 and 3 month clinical outcomes.</i>	
<i>Role: Co-I</i>	
<i>Total Direct Costs \$20,000</i>	
Grant No. (PI) Lee	Dates of Award 1/1/2022-12/31/24
Agency NIDA	Percent Effort 0
<i>Title Phase 1 Dose-Escalation Study of Dihydromyricetin (DHM) to Treat Alcohol-Associated Liver Disease</i>	
<i>Description We are assessing the safety and pharmacokinetics of dihydromyricetin in a phase I dose-escalation study.</i>	
<i>Role: Principal Investigator</i>	
<i>Total Direct Costs \$50,000</i>	
Grant No. (PI) Lee	Dates of Award 1/1/2022-12/31/24
Agency NIAAA	Percent Effort 0
<i>Title Assessing Feasibility to Conduct Clinical-Translational Research in an Alcohol-Associated Hepatitis Bridge Clinic (ABC) at a Safety-Net Hospital</i>	
<i>Description We are assessing the feasibility of forming a prospective observational cohort among patients with severe alcohol-associated hepatitis at a novel multi-disciplinary clinic at a safety-net hospital.</i>	
<i>Role: Principal Investigator</i>	
<i>Total Direct Costs \$54,000</i>	

GRANT SUPPORT – PAST:

Grant No. (PI) DK060414 (Maher)
Agency: NIDDK
Title: T32 Training Grant
Description: T32 Training Grant
Role: Awardee
Total Direct Costs N/A

Dates of Award: 2017-2019
Percent Effort: 75%

Grant No. (PI)
Agency
Title
Description
Role:
Total Direct Costs

Dates of Award
Percent Effort

ISSUED AND PENDING PATENTS: N/A

Patent Holder Names. Title. Institution. File #. Reference #. US Patent and Trademark Serial No.

INVITED LECTURES, SYMPOSIA, KEYNOTE ADDRESSES:

Year	Type	Title, Location
2021	Lecture	Alcohol-Associated Hepatitis: New Treatments and Paradigms, Annual USC GI & Liver Diseases Update. Los Angeles, CA.
2021	Lecture	Management of Substance Use Disorders in Liver Disease. AASLD Liver Meeting. General Hepatology Update. Anaheim, CA
2021	Lecture	How to Optimize your Fellowship Time. AASLD Liver Meeting. Career Development Workshop. Anaheim, CA.
2021	Lecture	Early Liver Transplantation (LT) for Alcohol-Associated Liver Disease. Southern California Society of Gastroenterology. Laguna Beach, CA.
2021	Lecture	Refining Selection for Early Liver Transplantation for Alcohol-Associated Hepatitis. California Digestive Diseases Research Center Consortium Symposium. San Francisco, CA.
2021	Symposia	Feasibility of clinical-translational research in Alcohol-associated hepatitis Bridge Clinic after hospitalization. Southern California Research Center for ALPD & Cirrhosis Annual Sympsium. Los Angeles, CA.
2021	Symposia	Phase 1 Dose-Escalation Study for Dihydromyricetin (DHM) to Treat Alcohol-Associated Liver Disease. USC Institute for Addiction Science Annual Retreat. Los Angeles, CA.
2022	Lecture	Impact of Liver Transplantation on Clinical Trials for Alcohol-Associated Hepatitis. DURECT West Divisional Meeting. San Francisco, CA.
2022	Lecture	Impact of Liver Transplantation on Clinical Trials for Alcohol-Associated Hepatitis. DURECT Central Divisional Meeting. Chicago, IL.
2022	Lecture	Liver Transplantation for Alcohol-Associated Hepatitis: Implications for Clinical Trial Design. NIAAA Public Meeting: Designing Clinical Trials to Integrate Treatment of Alcohol Use Disorders in Patients with Alcohol-Associated Liver Disease. Bethesda, MD.
2022	Lecture	US Experience in Early Liver Transplantation for Alcohol-Associated Hepatitis: Results from the ACCELERATE-AH Consortium. AASLD Emerging Topic Conference: Controversies and Consensus in Alcohol-Associated Liver Disease. Philadelphia, PA.
2022	Lecture	Pathophysiology of Alcohol-Associated Liver Disease and Treatments for Alcohol-Associated Hepatitis. Canadian Association for the Study of the Liver Conference on Alcohol-Associated Liver Disease. Vancouver, Canada.
2022	Lecture	Integrated Care Models: Multidisciplinary Clinic for Management of Alcohol-Associated Liver Disease. Canadian Association for the Study of the Liver Conference on Alcohol-Associated Liver Disease. Vancouver, Canada.
2022	Lecture	

		Acute-on-Chronic Liver Failure in Determining Futility of Liver Transplantation. AASLD Liver Meeting. Post-Graduate Course. Washington, DC.
2022	Symposia	Linkage of care after hospitalization for alcohol-associated hepatitis in a safety-net hospital. Southern California Research Center for ALPD & Cirrhosis Annual Sympsium. Los Angeles, CA.
2022	Symposia	Dihydromyricetin (DHM) to Treat Alcohol-Associated Liver Disease. USC Institute for Addiction Science Annual Retreat. Los Angeles, CA.
2023	Lecture	Covert Alcohol Use in "NASH". NASH-TAG Conference. Park City, UT.
2023	Lecture	Early Liver Transplantation for Alcohol-Associated Liver Disease: Update in Policy and Practice. Donor Alliance Conversation Series: Managing Alcohol use Disorder and Marijuana Use in Transplant Candidates. Atlanta, GA.
2023	Lecture	Identifying Risk of Alcohol Recurrence After Liver Transplantation. International Liver Transplant Society Congress. Rotterdam, Netherlands.
2023	State-of-the-Art Lecture	Controversies and Consensus in Alcohol-Associated Liver Disease: Past, Present and Future. Digestive Diseases Week. Chicago, IL.
2023	Lecture	Alcohol-Associated Liver Disease: Through the Ages and into the Future. Chilean Hepatology Association Meeting. Santiago, Chile.
2023	Lecture	Post-Transplant Monitoring of Alcohol Use and Interventions to Reduce Post-Transplant Alcohol Use. AASLD Liver Meeting. Boston, MA.
2023	Lecture	Mandates and best practices for liver transplant in alcohol-associated liver disease: is it time for regulation and national policy reform?. AASLD Liver Meeting. Boston, MA.
2023	Lecture	Dangerous Health Effects of Alcohol: What your Patients and Clients Need to Know. LA County Department of Public Health Substance Abuse Prevention and Control 11 th Community Seminar. Los Angeles, CA.
2024	Lecture	Liver transplantation for alcohol-associated liver disease: More than surgery. Chronic Liver Disease Foundation Liver Connect Annual Meeting. Scottsdale, AZ.
2024	Lecture	Strategies for identification of at-risk individuals for ALD detection and progression in the US. Workshop on reducing ALD burden through early screening and management in the general population. National Institute on Alcohol Abuse and Alcoholism (NIAAA). Bethesda, DC.
2024	Lecture	Early liver transplantation for alcohol related liver disease and history of decompensation. Digestive Diseases Week. Washington DC, DC.
2024	Lecture	Designing clinical trials to address alcohol use disorder in patients with alcohol-associated liver disease. Research Society on Alcohol Annual Scientific Meeting. Minneapolis, MI.
2024	Lecture	How to have a healthy mentorship relationship. Latin American Association for the Study of the Liver Annual Congress. Santiago, Chile.
2024	Lecture	Potential novel MetALD biomarkers to diagnose and predict liver disease progression. San Diego MetALD Conference: Opportunities and Challenge in Biomarkers and Clinical Drug Development. San Diego, CA.
2024	Lecture	Behind the Scene of Steatotic Liver Disease: From Research Idea to High-Impact Publication. AASLD Liver Meeting. San Diego, CA.
2024	Lecture	Meet-the-Experts: Expanding the Frontiers for Liver Transplantation in Severe Alcohol-Associated Hepatitis. AASLD Liver Meeting. San Diego, CA.

INVITED GRAND ROUNDS, CME LECTURES

2016	Grand Rounds	Early Liver Transplantation in Alcoholic Hepatitis: Science, Ethics, and Controversy. Drexel University Hahnemann Grand Rounds. Philadelphia, PA.
2019	Grand Rounds	Early Liver Transplantation for Alcoholic Hepatitis. Keck School of Medicine of USC Grand Rounds. Los Angeles, CA.
2021	Grand Rounds	Early Liver Transplantation (LT) for Alcohol-Associated Liver Disease, Keck School of Medicine USC Grand Rounds. Los Angeles, CA.
2022	Grand Rounds	Early Liver Transplantation (LT) for Alcohol-Associated Liver Disease (ALD): An Evolution of Practice and Policy, Rush Medical Center Gastroenterology Grand Rounds. Chicago, IL.
2022	Grand Rounds	Early Liver Transplantation for Alcohol-Associated Liver Disease: Recent Advances in Policy and Practice. Columbia University Gastroenterology Grand Rounds. New York City, NY.
2024	Grand Rounds	Early Liver Transplantation for Alcohol-Associated Liver Disease: From Research to Standard of Care. Tufts University Abdominal Transplantation Grand Rounds. Boston, MA.
2024	Grand Rounds	Early Liver Transplantation for Alcohol-Associated Liver Disease. New York University Hepatology and Liver Transplantation Grand Rounds. New York City, NY.
2024	Grand Rounds	Early Liver Transplantation for Alcohol-Associated Liver Disease: How Research Can Transform Clinical Practice, Policy, and Innovation. Baylor College of Medicine Hepatology and Liver Transplantation Grand Rounds. Houston, TX.
2024	Grand Rounds	The Evolution of Early Liver Transplantation for Alcohol-Associated Liver Disease: From Research to Standard of Care. California Pacific Medical Center Liver Transplantation Grand Rounds. San Francisco, SF.
2024	Grand Rounds	Early Liver Transplantation for Alcohol-Associated Liver Disease: How Research Can Transform Clinical Practice, Policy, and Innovation. University of Wisconsin Gastroenterology and Hepatology Grand Rounds. Madison, WI.
2024	Grand Rounds	Early Liver Transplantation for Alcohol-Associated Liver Disease: How Research Can Transform Clinical Practice, Policy, and Innovation. University of Wisconsin Division of Transplantation Grand Rounds. Madison, WI.
2024	Grand Rounds	Early Liver Transplantation for Alcohol-Associated Liver Disease: How Research Can Transform Clinical Practice, Policy, and Innovation. University of California San Francisco Liver Center Seminar. San Francisco, CA.

THESIS: N/A

Year Degree

Institution

Title

PUBLICATIONS:

REFEREED JOURNAL ARTICLES:

1. Lee BP, Molina J, Kim S, Dodge JL, Terrault NA. Association of Alcohol and Incremental Cardiometabolic Risk Factors with Liver Disease: A National Cross-Sectional Study. *Clin Gastroenterol Hepatol*. Accepted.
2. Elhence H, Brar G, Dodge JL, Lee BP. Healthcare Contact Days Pre- and Post-Liver Transplant in Patients with Cirrhosis: A National Cohort Study. *Clin Transl Gastroenterol*. E-pub ahead of print. PMID: 39835687.
3. Arab JP, Diaz LA, Rehm J, Im G, Arrese M, Kamath PS, Lucey MR, Mellinger J, Thiele M, Thursz M, Bataller R, Burton R, Chokshi S, Francque SM, Krag A, Lackner C, Lee BP, Liangunsakul S, MacClaim C, Mandrekar P, Mitchell MC, Morgan MY, Morgan TR, Pose E, Shah VH, Shawcross D, Sheron N, Singal AK, Stefanescu H, Terrault N, Trepo E, Moreno C, Louvet A, Mathurin P. Metabolic Dysfunction and Alcohol-related Liver Disease (MetALD): Position statement by an expert panel on alcohol-related liver disease. *J Hepatol*. 2024. E-pub ahead of print. PMID: 39608457.

4. Ayyala-Somayajula D, Dodge JL, Leventhal AM, Terrault NA, Lee BP. Trends in Alcohol Use after the COVID-19 Pandemic: A National Cross-Sectional Study. *Ann Intern Med*. 2024. E-pub ahead of print. PMID: 39527820.
5. Menon G, Metoyer GT, Li Y, Chen Y, Bae S, Lee BP, Loarte-Campos PC, Orandi BJ, Segev DL, McAdams-Demarco MA. Kidney transplantation among presumed undocumented immigrants after changes in US state policies. *JAMA Intern Med*. 2025 Jan;185(1):116-118. PMID: 39527079.
6. Edwards B, Ramirez S, Pappas J, Dodge JL, Han H, Kahn J, Ahearn A, Terrault NA, Lee BP. The University of Southern California Psychosocial Checklist: A Novel Tool to Remotely Screen Transplant Candidates with Alcohol-Associated Liver Disease Prior to Hospital Transfer. *Liver Transpl*. 2024. E-pub ahead of print. PMID: 39330947.
7. Ayyala-Somayajula D, Bottyan T, Shaikh S, Lee BP, Cho SH, Dodge JL, Terrault NA, Han H. Safety of acamprosate for alcohol use disorder post-liver transplant: a pilot randomized controlled trial. *Liver Transpl*. 2024. E-pub ahead of print. PMID: 39225670.
8. Elhence H, Dodge JL, Flemming JA, Lee BP. Emergency Department Utilization and Outcomes among Adults with Cirrhosis from 2008 to 2022 in the United States. *Clin Gastroenterol Hepatol*. 2024. E-pub ahead of print. PMID: 39181424.
9. Dukewich M, Dodge JL, Lucey MR, Rice JP, Shetty K, Jakhete N, Im GY, Weinberg EM, Hsu C, Smith C, Ghobrial RM, Therapondos G, Shoreibah M, Aryan M, Eswaran S, Fix OK, Maddur H, Terrault NA, Lee BP. The Survival Benefit of Re-abstinence after Harmful Alcohol Use Following Early Liver Transplant for Severe Alcohol-Associated Hepatitis: A Multi-Center ACCELERATE Study. *Am J Gastroenterol*. 2024. E-pub ahead of print. PMID: 38994850.
10. Lee BP, Witkiewitz K, Mellinger J, Anania FA, Bataller R, Cotter TG, Curtis, B, Dasarathy S, Demartini KS, Diamond I, Diazgranados N, DiMartini AF, Falk DE, Fernandez AC, German MN, Kamath PS, Kidwell KM, Leggio L, Litten R, Louvet A, Lucey MR, McCaul ME, Sanyal AJ, Singal AK, Sussman NL, Terrault NA, Thusz MR, Verna EC, Radaeva S, Nagy LE, Mitchell MC. Designing Clinical Trials to Address Alcohol Use and Alcohol-Associated Liver Disease: An Expert Panel Consensus Statement. *Nat Rev Gastroenterol Hepatol*. 2024 Sep;21(9):626-645. PMID: 38849555.
11. Elhence H, Dodge JL, Kahn JA, Lee BP. Characteristics and Outcomes among U.S. Commercially Insured Transgender Adults with Cirrhosis: A National Cohort Study. *Am J Gastroenterol*. 2024 Dec;119(12):2455-2461. PMID: 38916204.
12. Danpanichkul P, Chen VL, Chaiyakunapruk N, Auttaphracha T, Konagarin S, Ng CH, Duangsonk K, Muthiah MD, Sukphutanant B, Sim B, Huang DQ, Seko Y, Lee BP, Takahashi H, Noureddin M, Lazarus JV, Diaz LA, Arab JP, Mellinger JL, Liangpunsakul S, Wijarnpreecha K. Socio-economic association of alcohol use disorder and cardiovascular and alcohol-associated liver disease from 2010 to 2019. *Aliment Pharmacol Ther*. 2024 Aug; 60(3):340-349. PMID: 38808961.
13. Lee BP, Louvet A. Longitudinal Change of Alcohol Use is a Dynamic Contributor to Steatotic Liver Disease Progression. *Gastroenterology*. 2024 Jun;166(6):965-967. PMID: 38555072.
14. Danpanichkul P, Ng CH, Hao Tan DJ, Wijarnpreecha K, Huang DQ, Noureddin M, Nah B, Koh JH, Teng M, Lim WH, Ramadoss V, Thong E, Muthiah M, Wong ZY, Kaewdech A, Duangsonk K, Liu K, Sano T, Takahashi H, Chen V, Lee BP. The global burden of alcohol-associated cirrhosis and cancer in young and middle-aged adults. *Clin Gastroenterol Hepatol*. E-pub ahead of print. PMID: 38428708.
15. Lim WH, Tay P, Ng CH, Tan DJH, Ong C, Koh JH, Teng M, Chee D, Wong ZY, Kawaguchi T, Takahashi H, Muthiah M, Tan EXX, Wijarnpreecha K, Lee GH, Noureddin M, Lee BP, Mathurin P, Loomba R, Huang DQ. Meta-analysis: Prevalence and impact of alcohol abstinence in alcohol-associated cirrhosis. *Aliment Pharmacol Ther*. 2024 Mar;59(6):730-741. PMID: 38303565.

16. Cullaro G, Ge J, Lee BP, Lai JC, Wadhwani SI. Association between neighborhood-based material deprivation and liver transplant waitlist registrants demographics and mortality. *Clin Transplant*. 2024 Jan;38(1):e15189. PMID: 37937349.
17. Lee BP, Dodge JL, Terrault NA. National Prevalence Estimates for Steatotic Liver Disease and Sub-Classifications using Consensus Nomenclature. *Hepatology*. 2024 Mar;79(3):666-673. PMID: 37732946.
18. Elhence H, Dodge JL, Lee BP. Association of Renin-Angiotensin System Inhibition with Liver-Related Events and Mortality in Compensated Cirrhosis. *Clin Gastroenterol Hepatol*. 2024 Feb;22(2):315-323:e17. PMID: 37495200.
19. Lee BP, Dodge JL, Mack WJ, Leventhal AM, Terrault NA. National Trends in Alcohol Use, Metabolic Syndrome, and Liver Disease from 1999 to 2018. *Ann Intern Med*. 2023 Jun;176(6):879-882. PMID: 37155990.
20. Ayyala-Somayajula D, Dodge JL, Farias A, Terrault NA, Lee BP. Healthcare Affordability and Effects on Mortality among Adults with Liver Disease from 2004-2018 in the United States. *J Hepatol*. 2023 Aug;79(2):329-339. PMID: 37023857.
21. Elhence H, Dodge JL, Farias A, Lee BP. Quantifying Days at Home in Patients with Cirrhosis: A National Cohort Study. *Hepatology*. 2023 Aug;78(2):518-529. PMID: 36994701.
22. Hsu CC, Dodge JL, Weinberg E, Im G, Ko J, Davis W, Rutledge S, Dukewich M, Shoreibah M, Aryan M, Vosooghi A, Lucey M, Rice J, Terrault NA, Lee BP. Multi-Centered Study of Patient Outcomes after Declined for Early Liver Transplantation in Severe Alcohol-Associated Hepatitis. *Hepatology*. 2023 Apr 1;77(4):1253-1262. PMID: 36651183.
23. Lee BP, Dodge JL, Terrault NA. Geographic Density of Gastroenterologists is Associated with Decreased Mortality from Alcohol-Associated Liver Disease. *Clin Gastroenterol Hepatol*. 2023 Jun;21(6):1542-1551. PMID: 35934291.
24. Weinberg EM, Dukewich M, Jakhete N, Stonesifer E, Im GY, Lucey MR, Shetty K, Rice JP, Victor DW, Ghobrial MR, Shetty A, Rutledge SM, Florman SS, Hsu C, Shoreibah M, Aryan M, Orandi BJ, Han H, Terrault N, Lee BP. Early Liver Transplantation for Severe Alcohol-Associated Hepatitis and a History of Prior Liver Decompensation. *Am J Gastroenterol*. 2022 Dec;117(12):1990-1998. PMID: 35853462.
25. Leventhal AM, Cho J, Ray LA, Liccardo Pacula R, Lee BP, Terrault N, Pedersen E, Lee JO, Davis JP, Jin H, Huh J, Wilson JP, Whaley RC. Alcohol use trajectories among U.S. adults during the first 42 weeks of the COVID-19 pandemic. *Alcohol Clin Exp Res*. 2022 Jun; 46(6):1062-1072. PMID: 35532741.
26. Lee BP, Roth N, Rao P, Im GY, Vogel AS, Hasbun J, Roth Y, Shenoy A, Arvelakis A, Ford L, Dawe I, Schiano TD, Davis JP, Rice JP, Eswaran S, Weinberg E, Han H, Hsu C, Fix OK, Maddur H, Ghobrial RM, Therapondos G, Dilkina B, Terrault NA. Artificial intelligence to identify harmful alcohol use after early liver transplant for alcohol-associated hepatitis. *Am J Transplant*. 2022 Jul;22(7):1834-1841. PMID: 35416409.
27. Mueller PP, Chen Q, Ayer T, Nemutlu GS, Hajjar A, Bethea ED, Peters MLB, Lee BP, Janjua NZ, Kanwal F, Chhatwal J. Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication. *J Hepatol*. 2022 Jul;77(1):55-62. PMID: 35157959.
28. Kwan AC, Wei J, Lee BP, Luong E, Salto G, Nguyen TT, Botting PG, Liu Y, Ouyang D, Ebinger JE, Li D, Noureddin M, Thomson L, Berman DS, Merz CNB, Cheng S. Subclinical hepatic fibrosis is associated with coronary microvascular dysfunction by myocardial perfusion reserve index: a retrospective cohort study. *Int J Cardiovasc Imaging*. 2022 Feb 02. E-pub ahead of print. PMID: 3510770.
29. Lee BP, Cullaro G, Vosooghi A, Yao F, Panchal S, Goldberg DS, Terrault NA, Mahmud N. Discordance in categorization of acute-on-chronic liver failure in the United Network for Organ Sharing database. *J Hepatol*. 2022 May;76(5):1122-1126. PMID: 35074470.

30. Lee BP, Dodge JL, Terrault NA. Medicaid Expansion and Variability with Mortality: A National Observational Cohort Study. *Lancet Public Health*. 2022 01;7(1)e48-e55. PMID: 34863364.

31. Lee BP, Dodge JL, Terrault NA. Changes and Mediators of Survival Disparity among Black Liver Transplant Recipients in the United States. *Am J Transplant*. 2021 Aug 12;21(12):3883-3893. PMID: 34374495.

32. Lee BP, Dodge JL, Leventhal AM, Terrault NA. Retail Alcohol and Tobacco Sales During COVID-19. *Ann Intern Med*. 2021 Jul;175(7):1027-1029. PMID: 33646843.

33. Lee BP, Dodge JL, Terrault NA. Excess Mortality after Liver Transplantation in Young Women with Alcohol-Associated Liver Disease. *Am J Gastroenterol*. 2021 03 01;116(3):551-559. PMID: 33136566.

34. Mellinger JL, Shedd K, Winder GS, Fernandez AC, Lee BP, Waljee J, Fontana R, Volk ML, Blow FC, Lok AS. *Liver Int*. 2021 May;41(5):1012-1019. PMID: 33529460.

35. Lee BP, Im GY, Rice JP, Lazar A, Weinberg E, Han H, Maddur H, Ghobrial RM, Therapondos G, Hsu C, Fix OK, Eswaran S, Shetty K, Chhatwal J, Dalgic OO, Jakhete N, Mobley C, Victor DW, Mehta N, Dinges L, Rinella M, Schiano TD, Lucey MR, Terrault N. Patterns of Alcohol Use After Early Liver Transplantation for Alcoholic Hepatitis. *Clin Gastroenterol Hepatol*. 2022 Feb;20(2):409-418.e5. PMID: 33279780.

36. Lee BP, Vittinghoff EV, Pletcher MJ, Dodge JL, Terrault NA. Medicaid Policy and Liver Transplant for Alcohol-Associated Liver Disease. *Hepatology*. 2020 Jul;72(1):130-139. PMID: 31705545.

37. Cullaro G, Verna EC, Lee BP, Lai JC. Chronic Kidney Disease in Liver Transplant Candidates: A Rising Burden Impacting Post-Liver Transplant Outcomes. *Liver Transpl*. 2020 Apr;26(4):498-506. PMID: 31785069.

38. Lee BP, Terrault NA. Liver Transplantation in Unauthorized Immigrants in the United States. *Hepatology*. 2020 May;71(5):1802-1812. PMID: 31487391.

39. Lee BP, Samur S, Dalgic OO, Bethea ED, Lucey MR, Weinberg E, Hsu C, Rinella ME, Im GY, Fix OK, Therapondos G, Han H, Victor DW, Voigt MD, Eswaran S, Terrault NA, Chhatwal J. Model to Calculate Harms and Benefits of Early Vs Delayed Liver Transplantation for Patients with Alcohol-Associated Hepatitis. *Gastroenterology*. 2019 Aug;157(2):472-480. PMID: 30998988.

40. Lee BP, Im GY, Rice JP, Weinberg E, Hsu C, Fix OK, Therapondos G, Han H, Victor DW, Eswaran S, Maddur H, Terrault NA. Underestimation of Liver Transplantation for Alcoholic Hepatitis in the National Transplant Database. *Liver Transpl*. 2019 May;25(5):706-711. PMID: 30882995.

41. Lee BP, Vittinghoff EV, Hsu C, Han H, Therapondos G, Fix OK, Victor DW, Dronamraju D, Im GY, Voigt MD, Rice JP, Lucey MR, Eswaran S, Chen PH, Li Z, Maddur H, Terrault NA. Predicting Low-Risk for Sustained Alcohol Use After Early Liver Transplant for Acute Alcoholic Hepatitis: The Sustained Alcohol Use Post-Liver Transplant Score. *Hepatology*. 2019 Apr;69(4):1477-1487. PMID: 30561766.

42. Lee BP, Vittinghoff EV, Dodge JL, Cullaro G, Terrault NA. National Trends and Long-Term Outcomes of Liver Transplantation for Alcohol-Associated Liver Disease. *JAMA Intern Med*. 2019;179(3):340-348. PMID: 30667468.

43. Lee BP, Mehta N, Platt L, Gurakar A, Rice JP, Lucey MR, Im GY, Therapondos G, Han H, Victor DW, Fix OK, Dinges L, Dronamraju D, Hsu C, Voigt MD, Rinella ME, Maddur H, Eswaran S, Hause J, Foley D, Ghobrial RM, Dodge JL, Li Z, Terrault NA. Outcomes of Early Liver Transplantation for Patients with Severe Alcoholic Hepatitis. *Gastroenterology*. 2018 Aug;155(2):422-430.e1. PMID: 29655837.

44. Lai CL, Wong DK, Ip P, Seto WK, Fung J, Huang FY, Lee BP, Cullaro G, Wu R, Cheng C, Yuen J, Ngai V, Yuen MF. Reduction of Covalently Closed Circular DNA with Treatment in Chronic Hepatitis B. *J Hepatol*. 2017;66(2):275-281. PMID: 27639844.

45. Lee BP, Chen PH, Haugen C, Hernaez R, Gurakar A, Philosophe B, Dagher N, Moore SA, Li Z, Cameron

AM. Three-Year Results of a Pilot Program in Early Liver Transplantation for Severe Alcoholic Hepatitis. *Ann Surg.* 2017;265(1):20-29. PMID: 27280501.

46. He N, Zahirieh A, Mei Y, Lee B, Senthilnathan S, Wong B, Mucha B, Hildebrandt F, Cole DE, Cattran D, Pei Y. Recessive NPHS2 (Podocin) Mutations Are Rare in Adult-Onset Idiopathic Focal Segmental Glomerulosclerosis. *Clin J Am Soc Nephrol* 2: 31-37, 2007. PMID: 17699384.

REFEREED JOURNAL ARTICLES IN PRESS: N/A

Format: Authors, Title. *Journal*. Volume #(Suppl ##):Page-Page, Year. PMID#, PMCID#, *Narrative describing personal contribution*.

REFEREED REVIEWS, CHAPTERS, AND EDITORIALS: N/A

Format: Authors, Title. *Publication*. Volume #(Suppl ##):Page-Page, Year. PMID#, PMCID#

1. Lee BP, Terrault NA. Liver Transplantation for Alcohol-Associated Liver Disease: A Call for National Standards of Best Practices to Monitor and Bridge Disparities in Access and Outcomes. *Am J Transpl.* 2023 08;23(8):1097-1101. PMID: 37023857.
2. Lee BP, Terrault NA. Return to Alcohol Use After Liver Transplant: Patterns and Surveillance. *Clin Liver Dis.* 2019;12(6):160-164. PMID: 30988935.
3. Rice JP, Lee BP. Early Liver Transplantation for Alcohol-Associated Liver Disease: Need for Engagement and Education of All Stakeholders. *Hepatol Commun.* 2019 Aug;3(8):1019-1021. PMID: 31388622.
4. Lee BP, Terrault NA. Liver-related mortality in the United States: hepatitis C declines, non-alcoholic fatty liver disease and alcohol rise. *Transl Gastroenterol Hepatol.* 2019;4:19. PMID: 30976722.
5. Lee BP, Li Z. Alcohol Abuse and Liver Disease. *Gastroenterology.* 2018;154(1):254-255.
6. Lee BP, Terrault NA. Early liver transplantation for severe alcoholic hepatitis: moving from controversy to consensus. *Curr Opin Organ Transplant.* 2018 Apr;23(2):229-236. PMID: 29389821.

REFEREED ON-LINE PUBLICATIONS: N/A

Format: Authors. Title. *Publication*, URL, Year. PMID#, PMCID#

CLINICAL COMMUNICATION: (CASE REPORTS, LETTERS): N/A

Authors. Title. *Journal* Volume(Suppl ##):Page-Page, Year. PMID#, PMCID#

1. Lee BP, Dodge JL, Terrault NA. Liver Transplant for Alcohol-Associated Liver Disease Continues to Rise 2-Years into the COVID-19 Pandemic Especially Among Young Adults. *J Hepatol.* 2023 04;78(4):e139-e141. PMID: 36567054.
2. Lee BP, Terrault NA. Advocacy for Equity in Transplantation Access for Alcohol-Associated Liver Disease: How Research Changed Medi-Cal Policy. *Gastroenterology.* 2022 Sep;163(3):539-542. PMID: 35577123.

CLINICAL COMMUNICATION: (PUBLISHED CLINICAL TRIAL COMMUNICATIONS): N/A

Authors. Title. *Journal* Volume(Suppl ##):Page-Page, Year. PMID#, PMCID#

NON-REFEREED JOURNAL ARTICLES, REVIEWS, OR OTHER COMMUNICATIONS: N/A

Format: Authors, Title. *Journal*. Volume #(Suppl ##):Page-Page, Year. PMID#, PMCID#, *Narrative describing personal contribution*.

BOOKS, MONOGRAPHS, AND TEXT BOOKS: N/A

Authors. Title. *Publication* Volume(Suppl ##):Page-Page, Year.

LETTERS TO THE EDITOR:

Authors. Title. *Publication* Volume(Suppl ##):Page-Page, Year. PMID#, PMCID#

1. Lee BP, Im GY, Lucey MR, Terrault NA. Reply. *Gastroenterology*. 2019 Jan;156(3):286-287. PMID: 30472234.

ABSTRACTS AND PRESENTATIONS:

1. Im GY, Lee BP, Rice JP, Lazar A, Weinberg E, Han H, Maddur H, Ghobrial RM, Therapondos G, Hsu C, Fix OK, Eswaran S, Shetty K, Chhatwal J, Dalgic OO, Jakheti N, Victor DW, Mehta N, Dinges L, Rinella M, Lucey MR, Terrault N. Patterns of Alcohol Use after Early Transplantation for Alcoholic Hepatitis. AASLD Transplant Plenary Session, Nov 10, 2019. San Francisco, CA.
2. Lee BP, Rinella ME, Im GY, Rice JP, Fix OK Therapondos G, Han H, Victor DW, Weinberg E, Hsu C, Voigt MD, Maddur H, Eswaran S, Foley D, Ghobrial RM, Dinges L, Dodge JL, Mehta N, Lucey MR, Terrault NA. Patterns and Predictors of Alcohol Use after Early Liver Transplant for Alcoholic Hepatitis. ATC Parallel Session Oral Presentation, June 4, 2019. Boston, MA.
3. Lee BP, Rinella ME, Im GY, Rice JP, Fix OK Therapondos G, Han H, Victor DW, Weinberg E, Hsu C, Voigt MD, Maddur H, Eswaran S, Foley D, Ghobrial RM, Dinges L, Dodge JL, Mehta N, Lucey MR, Terrault NA. Patterns and Predictors of Alcohol Use after Early Liver Transplant for Alcoholic Hepatitis. EASL Parallel Session Oral Presentation, Apr 14, 2019. Vienna, Austria.
4. Lee BP, Vittinghoff EV, Hsu C, Han H, Therapondos G, Fix OK, Victor DW, Dronamraju D, Im GY, Voigt MD, Rice JP, Lucey MR, Eswaran S, Chen PH, Li Z, Maddur H, Terrault NA. Predicting Low-Risk for Sustained Alcohol Use After Early Liver Transplant for Acute Alcoholic Hepatitis: The SALT Score. AASLD Transplant Plenary Session, Nov 11, 2018. San Francisco, CA.
5. Lee BP, Im GY, Rice JP, Weinberg E, Therapondos G, Han H, Victor DW, Fix OK, Hsu C, Voigt MD, Maddur H, Eswaran S, Hause J, Foley D, Rinella ME, Ghobrial RM, Roth N, Dinges L, Dodge JL, Mehta N, Lucey MR, Terrault NA. Novel Predictor of Alcohol Use After Early Liver Transplantation (LT) for Severe Alcohol-Associated Hepatitis (AAH) and Impact on Long-Term (5-Year) Survival. AASLD Parallel Session Oral Presentation, Nov 11, 2018. San Francisco, CA.
6. Lee BP, Im GY, Dodge JL, Voigt MD, Rice JP, Lucey MR, Foley D, Platt L, Gurakar A, Mehta N, Therapondos G, Han H, Victor DW, Fix OK, Dinges L, Dronamraju D, Hsu C, Rinella ME, Maddur H, Eswaran S, Hause J, Ghobrial RM, Li Z, Terrault NA. ATC Parallel Session Oral Presentation, June 3, 2018. Seattle, WA.
7. Lee BP, Mehta N, Platt L, Gurakar A, Rice JP, Lucey MR, Im G, Therapondos G, Han H, Victor DW, Fix OK, Dinges L, Dronamraju D, Hsu CS, Voigt MD, Rinella ME, Maddur H, Eswaran S, Hause J, Foley DP, Dodge J, Li Z, Terrault N. Post-Transplant Outcomes from the Multi-Center American Consortium of Early Liver Transplantation for Alcoholic Hepatitis: (ACCELERATE-AH) Study. AASLD Transplant Plenary Session, Oct 22, 2017. Washington, DC.
8. Lee BP, Mehta N, Platt L, Im G, Therapondos G, Han H, Victor DW, Dronamraju D, Hanouneh I, Voigt M, Rinella ME, Eswaran S, Hause J, Hsu C, Dodge J, Li Z, Terrault N. U.S. Outcomes in Early Liver Transplantation for Alcoholic Hepatitis: Results from the American Consortium of Early Liver Transplantation for Alcoholic Hepatitis (ACCELERATE-AH). ILTS Plenary Session, May 27, 2017. Prague, Czech Republic.
9. Lee BP, Mehta N, Platt L, Im G, Therapondos G, Han H, Victor DW, Dronamraju D, Hanouneh I, Voigt M, Rinella ME, Eswaran S, Hause J, Hsu C, Dodge J, Li Z, Terrault N. U.S. Outcomes in Early Liver Transplantation for Alcoholic Hepatitis: Results from the American Consortium of Early Liver Transplantation for Alcoholic Hepatitis (ACCELERATE-AH). ATC Late-Breaking Abstract, May 2, 2017. Chicago, IL.

10. Lee BP, Chen PH, Haugen C, Hernaez R, Gurakar A, Philosophe B, Dagher N, Moore S, Li Z, Cameron AM. Three-Year Results of a Pilot Program in Early Liver Transplantation for Severe Alcoholic Hepatitis. *Controversies in Transplantation*, Mar 3, 2016. Breckenridge, CO.
11. Lee BP, Victor DW, Ghobrial RM, Rinella ME, Li Z. Early Liver Transplantation in Severe Alcoholic Hepatitis: A Multi-Center, Retrospective, Cohort Study. *DDW*, May 17, 2015. Chicago, IL.
12. Lee BP. Role of Liver Transplantation for Alcoholic Hepatitis: Should Patients with Acute Alcoholic Hepatitis be Denied Liver Transplantation Outright?. *DDW Academic Debates*, May 19, 2015. Chicago, IL.
13. Lee BP, Victor DW, Ghobrial RM, Rinella ME, Li Z. Early Liver Transplantation in Severe Alcoholic Hepatitis: The U.S. Experience. *AASLD*, November 8, 2014. Boston, MA.

Summary of Research Activities

I am passionate about improving health for patients with alcohol use, metabolic dysfunction, and liver disease, through: 1) early liver transplant for alcohol-associated hepatitis; 2) intersection of alcohol and obesity in the liver; 3) inequities in healthcare access; 4) public policy and advocacy; 5) clinical trial design, novel therapeutics and translational studies. I have successfully obtained funding through extramural (NIAAA), intramural (IAS, SC ALPD Centers) grants. This research has led to high impact factor first- and senior-author original manuscripts in *Annals of Internal Medicine*, *Lancet Public Health*, *JAMA Internal Medicine*, *Gastroenterology*, and *Journal of Hepatology*, among others. I founded and lead the NIH-funded ACCELERATE consortium, which is the largest multi-center consortium studying early liver transplantation in alcohol-associated liver disease. I was first-author of our seminal publication, which has been cited over 350 times since 2018, and was deemed one of the major advances between 2010-2019 in *Gastroenterology* and *Hepatology* by the editorial board of the *American Journal of Gastroenterology*. My research has changed national practice guidelines throughout North America, Europe, Latin America, and Asia. I am a leading expert in this field, having served as an invited lecturer and expert panelist throughout the US and internationally.

Significant Publications

1. Lee BP, Mehta N, Platt L, Gurakar A, Rice JP, Lucey MR, Im GY, Therapondos G, Han H, Victor DW, Fix OK, Dinges L, Dronamraju D, Hsu C, Voigt MD, Rinella ME, Maddur H, Eswaran S, Hause J, Foley D, Ghobrial RM, Dodge JL, Li Z, Terrault NA. Outcomes of Early Liver Transplantation for Patients with Severe Alcoholic Hepatitis. *Gastroenterology*. 2018 Aug;155(2):422-430.e1. PMID: 29655837.

I led this multi-center effort, which provided the first and largest granular US multi-center data regarding early liver transplantation for alcohol hepatitis, and led to changes in national practice.

2. Lee BP, Vittinghoff EV, Dodge JL, Cullaro G, Terrault NA. National Trends and Long-Term Outcomes of Liver Transplantation for Alcohol-Associated Liver Disease. *JAMA Intern Med*. 2019;179(3):340-348. PMID: 30667468.

This national study showed that early liver transplantation practices were being applied beyond alcohol hepatitis, into the broader alcohol cirrhosis population, and a significant driver to alcohol becoming the #1 indication for liver transplant in the USA. We showed that regional variation in adopting early transplant practices were leading to significant disparities in liver transplant.

3. Lee BP, Vittinghoff EV, Hsu C, Han H, Therapondos G, Fix OK, Victor DW, Dronamraju D, Im GY, Voigt MD, Rice JP, Lucey MR, Eswaran S, Chen PH, Li Z, Maddur H, Terrault NA. Predicting Low-Risk for Sustained Alcohol Use After Early Liver Transplant for Acute Alcoholic Hepatitis: The Sustained Alcohol Use Post-Liver Transplant Score. *Hepatology*. 2019 Apr;69(4):1477-1487. PMID: 30561766.

I led this multi-center effort, which produced the SALT score to predict alcohol relapse among transplant candidates for early liver transplant. A 2021 national survey shows that over a third of US transplant centers have adopted the SALT score, in addition to centers beyond the USA.

4. Lee BP, Im GY, Rice JP, Weinberg E, Hsu C, Fix OK, Therapondos G, Han H, Victor DW, Eswaran S, Maddur H, Terrault NA. Underestimation of Liver Transplantation for Alcoholic Hepatitis in the National Transplant Database. *Liver Transpl*. 2019 May;25(5):706-711. PMID: 30882995.

I led this multi-center effort, which showed that early liver transplantation was being underestimated in the national transplant registry. This led to an official national policy change in coding of alcohol liver disease in 2022.

5. Lee BP, Terrault NA. Liver Transplantation in Unauthorized Immigrants in the United States. *Hepatology*. 2020 May;71(5):1802-1812. PMID: 31487391.

I led a national study of liver transplant access and outcomes in unauthorized immigrants, which led OPTN (national regulatory organization for transplant) to release a new guidance document to address access to transplant for unauthorized immigrants in 2021 across the United States.

6. Lee BP, Vittinghoff EV, Pletcher MJ, Dodge JL, Terrault NA. Medicaid Policy and Liver Transplant for Alcohol-Associated Liver Disease. *Hepatology*. 2020 Jul;72(1):130-139. PMID: 31705545.

This national study showed the variability in financial coverage by Medicaid for early liver transplant for alcohol liver disease leading to geographic and socioeconomic disparities in transplant access. This data provided the impetus to directly petition to Medi-Cal leadership (13 million+ enrollees in California), successfully leading to official state-wide policy change in February 2022.

7. Lee BP, Dodge JL, Leventhal AM, Terrault NA. Retail Alcohol and Tobacco Sales During COVID-19. *Ann Intern Med*. 2021 Jul;175(7):1027-1029. PMID: 33646843.

This national study was the first to show an objective increase in alcohol and tobacco during COVID-19.

8. Lee BP, Dodge JL, Mack WJ, Leventhal AM, Terrault NA. National Trends in Alcohol Use, Metabolic Syndrome, and Liver Disease from 1999 to 2018. *Ann Intern Med*. 2023 Jun;176(6):879-882. PMID: 37155990.

I led a national study to show that the surge in alcohol liver deaths has not coincided with an increase in alcohol consumption, and may be due to the concomitant increase in co-factors such as obesity and other metabolic factors.

9. Lee BP, Dodge JL, Terrault NA. National Prevalence Estimates for Steatotic Liver Disease and Sub-Classifications using Consensus Nomenclature. *Hepatology*. 2024 Mar;79(3):666-673. PMID: 37732946.

This national study quantified the prevalence of steatotic liver disease and that “safe” amounts of alcohol for the liver may be lower than suggested by current practice.

10. Lee BP, Witkiewitz K, Mellinger J, Anania FA, Bataller R, Cotter TG, Curtis, B, Dasarathy S, Demartini KS, Diamond I, Diazgranados N, DiMartini AF, Falk DE, Fernandez AC, German MN, Kamath PS, Kidwell KM, Leggio L, Litten R, Louvet A, Lucey MR, McCaul ME, Sanyal AJ, Singal AK, Sussman NL, Terrault NA, Thusz MR, Verna EC, Radaeva S, Nagy LE, Mitchell MC. Designing Clinical Trials to Address Alcohol Use and Alcohol-Associated Liver Disease: An Expert Panel Consensus Statement. *Nat Rev Gastroenterol Hepatol*. 2024 Sep;21(9):626-645.

This consensus document provides guidelines for designing clinical trials in alcohol use and alcohol-associated liver disease, by a multidisciplinary task force of international experts convened by the NIAAA.

11. Ayyala-Somayajula D, Dodge JL, Leventhal AM, Terrault NA, Lee BP. Trends in Alcohol Use after the COVID-19 Pandemic: A National Cross-Sectional Study. *Ann Intern Med*. 2024. E-pub ahead of print.

I led this national study showing that increases in heavy alcohol use from the pandemic have been sustained beyond the pandemic.

SELECTED MEDIA AND TELEVISION APPEARANCES:

Format: Date, Title of presentation, Venue

1. January 15, 2025. Not drunk; not dry: what it means to be “soberish”. New York Times.
2. January 9, 2025. Alcohol carries new risks in middle age. New York Times.
3. January 3, 2025. US surgeon general sounds alarm about link between alcohol and cancer. CNN.
4. November 23, 2024. Alcohol use increased during the COVID-19 pandemic. A new study shows that it's still high. CNN.
5. November 11, 2024. At the Pandemic's Start, American Began Drinking More. They Still Are. New York Times.
6. August 21, 2023. He needed a liver transplant. But did risks outweigh the reward? ProPublica.
7. July 9, 2023. Georgia is taking Medicaid in the wrong direction. Washington Post.
8. June 18, 2023. Ozempic might help you drink and smoke less. Wall Street Journal.
9. May 16, 2023. Why undocumented immigrants struggle to receive organ transplants. New York Times.
10. February 17, 2023. What to know about alcohol use disorder and how to get treatment. USA Today.
11. February 17, 2023. Is any amount of alcohol safe? USA Today.
12. August 29, 2022. Psychedelics Show Promise for Treating Alcohol Addiction. NPR.
13. August 24, 2022. Psilocybin, Psychedelic Compound in Magic Mushrooms, Shown Effective for Alcohol Addiction. Wall Street Journal.
14. December 27, 2021. Medicaid Expansion Saved Lives in Affected States. US News.
15. October 10, 2021. In the quest for a liver transplant, patients are segregated by prior alcohol use. NPR.
16. August 23, 2021. Wine Didn't Make Me a Better Mom. Marieclaire.
17. August 5, 2021. Rate of Liver Transplants Surge as Alcohol Sales Boom During Pandemic. NBC News.
18. March 21, 2021. The Negative Effects of Increased Alcohol Consumption During Pandemic. NBC Nightly News.
19. March 17, 2021. Soaring Pandemic Alcohol Sales Cause Concern for Doctors. Forbes.
20. March 7, 2021. During COVID: More alcohol consumption, more hospital patients with liver disease. NPR.
21. February 10, 2021. Medical experts warn of pandemic-related rise in liver disease. Fox News.
22. February 10, 2021. Doctors voice concern over rise in alcohol-related liver disease amid pandemic. ABC News.
23. February 8, 2021. During COVID: More alcohol consumption, more hospital patients with liver disease. Press Play with Madeleine Brand; NPR News.
24. February 8, 2021. As alcohol abuse rises amid pandemic, hospitals see a wave of deadly liver disease. Los Angeles Times.

25. February 25, 2020. Alcohol is growing as a prime-time killer. US News & World Report.
26. January 23, 2019. Alcohol overtakes hepatitis C as the top reason for liver transplants. ABC News.
27. January 23, 2019. Alcohol-related disease overtakes hepatitis C as top reason for liver transplant. NBC News.

Summary of Media Appearances:

My research and advocacy has served as the basis, and I have provided clinical and research expertise for alcohol-related diseases in appearances with national media coverage, including with *New York Times*, *Washington Post*, *NBC Nightly News*, *Today Show*, *NPR*, *CNN*, *Forbes*, *Los Angeles Times*, and *Wall Street Journal*.